DanDrit Biotech applies to list on Nasdaq

In This List

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

27 Feb, 2018 | 02:57

Author Angelee Tabios
Theme Healthcare & Pharmaceuticals

DanDrit Biotech USA Inc. filed an application to list its common shares on the Nasdaq Capital Market following the acquisition of privately held Enochian Biopharma Inc.

The Danish biopharmaceutical company will change its name to Enochian BioSciences Inc. and relocate its headquarters to Los Angeles. It is currently listed on the OTC Pink market.

DanDrit specializes in developing immunotherapies for various types of cancer and is currently working on innovative treatments for HIV and colon cancer.